Strategic exploration of the implementation of China’s drug patent linkage system corresponding to international rules

WANG Yuan; SHAO Rong; YAN Jianzhou

doi:10.6039/j.issn.1001-0408.2022.21.02

您当前的位置：

首页 >

文章列表页 >

Strategic exploration of the implementation of China’s drug patent linkage system corresponding to international rules

更新时间：2023-02-22

- Strategic exploration of the implementation of China’s drug patent linkage system corresponding to international rules
- ZHONGGUO YAOFANG Vol. 33, Issue 21, Pages: 2566-2571(2022)
- 作者机构：
  
  中国药科大学药品监管科学研究院/国家药品监督管理局药品监管创新与评价重点实验室，南京　211100
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.21.02
  CLC： R951;D923.42
- Published：15 November 2022，
  
  Received：06 May 2022，
  
  Revised：07 September 2022，
扫描看全文
王媛,邵蓉,颜建周.对标国际规则的我国药品专利链接制度实施策略探索 ^Δ[J].中国药房,2022,33(21):2566-2571.

WANG Yuan,SHAO Rong,YAN Jianzhou.Strategic exploration of the implementation of China’s drug patent linkage system corresponding to international rules[J].ZHONGGUO YAOFANG,2022,33(21):2566-2571.
王媛,邵蓉,颜建周.对标国际规则的我国药品专利链接制度实施策略探索 ^Δ[J].中国药房,2022,33(21):2566-2571. DOI： 10.6039/j.issn.1001-0408.2022.21.02.

WANG Yuan,SHAO Rong,YAN Jianzhou.Strategic exploration of the implementation of China’s drug patent linkage system corresponding to international rules[J].ZHONGGUO YAOFANG,2022,33(21):2566-2571. DOI： 10.6039/j.issn.1001-0408.2022.21.02.

摘要

目的

从制度设计方面探索我国药品专利链接制度的实施策略，为鼓励药品创新和提升高质量仿制药发展水平提供参考。

方法

梳理我国药品专利链接制度相关政策文件，从制度实施现状出发总结我国药品专利链接制度目前取得的进步和面临的挑战；在此基础上，总结其他国家的成功经验和教训，结合我国基本国情，为我国药品专利链接制度的落地实施提出建议。结果与

结论

随着2020年修正版《中华人民共和国专利法》的出台，我国已基本完成该制度的顶层设计，但由于部分细则规定尚未完善，我国尚存在缺乏“拟制侵权”制度、专利信息登记缺乏审查及纠错机制、司法和行政途径链接不畅、等待期时长仍存争议、首仿药市场独占期制度相关细则不够明确等问题。建议我国建立“拟制侵权”制度和专利无效司法判决程序，调整等待期时长或上市审批依据，进一步明确首仿药定义及共同挑战专利的情形和市场独占期的消灭事由，同时加强相关部门职能链接程序，落实责任机制。

Abstract

OBJECTIVE

To explore the implementation strategy of China’s drug patent linkage system from the perspective of the system design， in order to encourage drug innovation and improve the development level of high-quality generic drugs.

METHODS

The current progress and challenges were summarized from the current situation of the implementation of China’s drug patent linkage system by sorting out the relevant policy documents of the system. On this basis， the successful experience and lessons of foreign countries were summarized to provide strategic suggestions for the implementation of China’s drug patent linkage system in combination with China’s basic national conditions. RESULTS &

CONCLUSIONS

With the introduction of the revised

Patent Law of the People

’

s Republic of China

in 2020， China had basically completed the top-level design of the system， but some rules and regulations had not been improved. There were still some problems， such as the lack of a “fake infringement” system in China， the lack of review and correction mechanisms for patent information registration， poor links between judicial and administrative channels， the dispute over the length of waiting period， and the lack of clarity of relevant rules for the exclusivity period system of the first generic drug market. It is recommended that China establish a “fake infringement” system and a judicial decision procedure for patent invalidation， adjust the length of the waiting period or the basis for market approval， further clarify the definition of the first generic drug， the circumstances of jointly challenging patents and the reasons for the elimination of the market exclusivity period， and strengthen the functional link procedures of relevant departments and implement the responsibility mechanism.

关键词

药品专利链接制度专利纠纷早期解决机制专利法仿制药

Keywords

early resolution mechanism for patent disputespatent lawgeneric drug

references

韩欣悦，聂洪涛.我国医药产品创新性与可及性的利益平衡及制度建构：以专利链接制度为例[J].中国药房，2021，32（18）：2177-2183.

赵乃瑄，杨壬淦.双层博弈视角下的中国药品专利链接制度移植与创新[J].科技与法律（中英文），2021（6）：65-73.

邱明东.全国首例药品专利链接诉讼案件宣判[EB/OL].（2022-04-15）[2022-04-20].https：//mp.weixin.qq.com/s/-9 SocP2TLE20Xw7me3OxNwhttps://mp.weixin.qq.com/s/-9SocP2TLE20Xw7me3OxNw.

关春媛.药品专利链接制度的国际发展及本土完善[J].中国发明与专利，2021，18（6）：52-60.

李辉辉.我国药品专利链接制度构建的法律问题研究[D].杭州：浙江工商大学，2020.

国家药品监督管理局药品审评中心.中国上市药品专利信息登记平台[EB/OL].[2022-03-29].https：//zldj.cde.org.cn/homehttps://zldj.cde.org.cn/home.

杨开元.我国台湾地区药品专利连结制度及相关启示[J].中国卫生法制，2021，29（6）：84-90.

魏聪，田甜，杜国顺，等.中国特色药品专利纠纷早期解决机制的制度设计：以国外经验与国内现状的对比为视角[J].中国新药杂志，2021，30（15）：1345-1354.

李晓秋，余晨.论新《专利法》中药品专利链接制度的确立及完善[J].中国科技论坛，2022（1）：131-138，160.

王广源.我国专利链接制度中拟制侵权问题研究[D].湘潭：湘潭大学，2020.

HARRIS T，NICOL D，GRUEN N. 2013 pharmaceutical patents review report[EB/OL].（2013-05-27）[2022-04-20]. https：//www.ipaustralia.gov.au/sites/default/files/2013-05-27_ppr_final_report.pdf?acsf_files_redirecthttps://www.ipaustralia.gov.au/sites/default/files/2013-05-27_ppr_final_report.pdf?acsf_files_redirect.

国家药品监督管理局药品审评中心.办事指南[EB/OL].[2022-04-20]. https：//www.cde.org.cn/main/guide/contentpage/545cf855a50574699b46b26bcb165f32https://www.cde.org.cn/main/guide/contentpage/545cf855a50574699b46b26bcb165f32.

毕马威中国.中国加速推进专利法改革：对创新药和仿制药未来发展的影响[EB/OL].（2021-02-01）[2022-04-20]. https：//www.sohu.com/a/447970692_120070887https://www.sohu.com/a/447970692_120070887.

罗雨佳.药品专利纠纷早期解决之批准等待期研究[D].上海：华东政法大学，2021.

杨令，田浩国，程远.中国药品研发专利激励制度研究：基于《专利法》第四次修订[J].科技和产业，2021，21（10）：219-222.

谢伟，马治国，张磊.中国药品专利链接体系化的路径选择研究[J].中国科技论坛，2021（5）：108-117.

翟珮玉.中国药品专利链接之专利挑战制度的优化研究[J].山东商业职业技术学院学报，2021，21（6）：63-70.

牛炬钦.浅谈美国的专利无效制度[EB/OL].（2020-05-03）[2022-04-20]. https：//www.sohu.com/a/392712367_120693751https://www.sohu.com/a/392712367_120693751.

曹红英，宋蓓蓓，王志超.药品专利纠纷早期解决机制国际比较研究[J].电子知识产权，2021（9）：4-14.

TGA. Therapeutic goods act 1989[EB/OL].（2018-02-28）[2022-04-20]. https：//www.tga.gov.au/sites/default/files/advertising-exemption-nurofen-ibuprofen.pdfhttps://www.tga.gov.au/sites/default/files/advertising-exemption-nurofen-ibuprofen.pdf.

CHOE J Y，YOON K A，LEE S. Korea：the new first battleground for the high stakes poker game of pharmaceutical patent litigation[J]. Pharm Pat Anal，2015，4（6）：409-413.

中华人民共和国最高人民法院.最高人民法院就《关于审理涉药品上市审评审批专利民事案件适用法律若干问题的规定》（征求意见稿）向社会公众公开征求意见[EB/OL].（2020-10-29）[2022-04-20]. https：//www.court.gov.cn/zixun-xiangqing-267401.htmlhttps://www.court.gov.cn/zixun-xiangqing-267401.html.

程永顺，吴丽娟.实施“药品专利链接制度”司法应当考虑解决的问题[EB/OL].（2020-04-04）[2022-04-20]. https：//baijiahao.baidu.com/s?id=1662945847410815584 &wfr=spider&for=pchttps://baijiahao.baidu.com/s?id=1662945847410815584&wfr=spider&for=pc.

刘玉君.新形势下我国药品专利链接制度的适用与完善[J].法制博览，2021（28）：135-136.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

中药仿制一致性评价的思考

原研与国产仿制抗菌药物药品说明书的对比分析

盐酸马尼地平片仿制药与原研药的溶出度一致性评价

CHINA PH ARMACY Volume 33，Number 13，July 15，2022 Semimonthly Table of Contents Discussion on development difficulties and countermeasures of complex preparations in China

Analysis on the linkage of 415 generic medicines passing consistency evaluation and essential medicine list ， medical insurance list and centralized procurement list from the perspective of medicine accessibility

Related Author

王茹茹何祖新

龚海虹林志强

吕亚军?蚩晓娜?谷志勇

SONG Bo

ZHENG Xiao

SHI Juan

CAO Feng

ZHANG Huan

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰